Moreover, double immune checkpoint blockade of TIGIT and PD-L1 in three different NB murine models (N1E-115, Neuro2a, and N18) led to superior survival outcomes compared to single treatment with PD-L1 [75]. Here, TIGIT is linked to neuroblastoma.